CUP AND HANDLE FORMING NEW PT 6.50+Price above 200 EMA. Bounced off-diagonal support. Bounced off 50% retracement. RSI Oversold. Confirmed trend reversal.
0LOV trade ideas
OVERSOLD, BOUNCED OFF TREND LINE, TESTED 50% RETRACEMENTOVERSOLD, BOUNCED OFF TREND LINE, TESTED 50% RETRACEMENT. Great price to buy in my opinion.
FDA gave breakthrough designation..Verastem announced it received FDA Breakthrough Therapy designation for VS-6766 with defactinib in recurrent low-grade serous ovarian cancer.
If the flag holds, it looks like it could hit around $4.60. Considering adding to my position today. But probably will just hold with what I have.
VSTM Verastem Inc. - Is VSTM forming a W on a weekly chart?Is VSTM forming a W on a weekly chart?
Decide for yourself.
Resistance @2,7 @4,7 @10,30 and the sky is above 19 $
Good luck and happy trading everyone!
VSTM Verastem - nice W forming - is this going to the sky soon? VSTM - nice W forming - is this going to the sky @ 19 $ and above ?
Nice volume and start of steady uptrend.
GOOD LUCK and enjoy investing
Target in sight. $vstmLooks to me like an ascending triangle breakout. Unfortunately, the volume is fairly week, but we'll see where it takes us.
I plan on taking profits in the yellow area. I might run a trailing stop loss when it enters that area and just let it run.
$vstm
$VSTM Verastem, Inc., Potential 20% UpsideVerastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
$VSTM Bullish opportunity targeting double current price 1.48Bullish setup formed by 3 red daily candles closing at same price . this pattern can lead to significant price change and RSI signal positively .. bullish long more likely with stoploss at 1.25 (not far away) risk reward (-20% vs +100%). to be watched closely!!
VSTM - My first sample analysisSTOCH RSI
- Borderline Overbought
ADX and DI
- DI + indicates uptrend
- ADX starting to get up the mid line may indicate strong uptrend
MACD
- MACD and signal indicator have crossed and is going uptrend
Bollinger bands
- show close tunneling may, may signal uptrend
REMARKS
monitor buy signals + analyse fundamentals
This is my first graph analysis
Clear Short trade as the stock falls back into the 1.05 - 1.10 lShorted here on the break of 1.68 lots of stops taken out weak into next month
Easy - LONG Verastem! Chart, Technicals, Cash, Upcoming news....
These guys have a COVID trial that starts June 30th and we have yet to see an 8-k or PR for it.
This is a great time to go long and setup for it....We are looking to finally establish 2.05 support...there are a LOT of shorts to come running home if we do so...
First time we will test with a healthier MACD and CMF on the week....STOCH and RSI look great as well....
not a ton of downside risk - if you want, let go if we break the 200day - but other than that this one is way too easy right now.
ENJOY THE FIRE WORKS <3
VERASTEM INCNASDAQ:VSTM
Here you go, friends, good instrument to long
If we form a pressure under the level, we'll go up well, don't miss it.
VSTM trendVSTM seems to have great potential up to $3 a share, and in the long trend it is below the average range. This past quarter earnings is better than the previous quarter.
RSI, MACD indicators are starting to look good?The RSI is near the bottom of its range. The MACD, though in a steep decline is showing that the indicators are closing in. With this stock having a history of sharp gains and losses it could be a really nice set up for some very sharp gains. Also note the huge gap down it took April 27 as there could be a nice gap fill.
Note. I am very new so do not make trades off of my advice. Hopefully someone with some experience will say a few things!
Be Blessed! I am in with a 2.00 average
Could this be a H&S play?Expcting $VSTM to go up to atleast $2.4 as with H&S pay as shown below. Long with Ave 1.88....
A cute stock to buy and hold for couple days Seems like it reached the bottom of the Bollinger band and resistance of the trendline. Also, RSI is low enough. After a little possible drop, it is very likely to go up sharply for a couple of days.
$VSTM Verastem upside targets Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
Long SetupAccumulation below 1.40 think this lasts another month of bouncing off 1.40. Can't ignore this setup as it looks similar to 2017. Long and will add. S/L below 1.16. Bio's can quickly turn down off dilution or study results so manage appropriately.
